CIK 0001447028 · Non-accelerated filer<br>Smaller reporting company
Arbutus Biopharma Corp
Sign in to watch- Ticker
- ABUS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- British Columbia, Canada
- Entity type
- operating
- EIN
- 980597776
- Phone
- 604-419-3200
- Business address
- 701 VETERANS CIRCLE, WARMINSTER, PA, 18974
- Former names
- TEKMIRA PHARMACEUTICALS CORP, TEKMIRA PHARMACEUTICALS Corp
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-14 | McElhaugh Michael J. Interim President & CEO | Grant or award · Stock Option (Right to Buy) | +718,800 | 718,800 | ||
| 2025-02-14 | HASTINGS DAVID C Chief Financial Officer | Grant or award | +90,100 | 249,824 | ||
| 2025-02-14 | HASTINGS DAVID C Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +365,800 | 365,800 | ||
| 2025-02-14 | Sims Karen Chief Medical Officer | Grant or award | +49,300 | 155,494 | ||
| 2025-02-14 | Sims Karen Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +200,300 | 200,300 | ||
| 2025-02-04 | HASTINGS DAVID C Chief Financial Officer | Sale 10b5-1 | −22,183 | $3.28 | $73K | 159,724 |
| 2025-02-04 | Sims Karen Chief Medical Officer | Sale 10b5-1 | −19,348 | $3.28 | $64K | 106,194 |
| 2025-02-04 | McElhaugh Michael J. Interim President & CEO | Sale 10b5-1 | −23,790 | $3.28 | $78K | 1,481,003 |
| 2025-02-04 | Naftzger J. Christopher General Counsel and CCO | Sale 10b5-1 | −11,333 | $3.28 | $37K | 86,244 |
| 2024-08-14 | MANCHESTER KEITH S Director | Option exercise | +54,915 | $0.56 | $31K | 54,915 |
| 2024-08-14 | MANCHESTER KEITH S Director | Sale | −8,846 | $3.69 | $33K | 46,069 |
| 2024-08-14 | MANCHESTER KEITH S Director | Option exercise · Stock Option (Right to Buy) | −54,915 | 0 | ||
| 2024-05-23 | BURGESS DANIEL D Director | Grant or award · Stock Option (Right to Buy) | +67,000 | 67,000 | ||
| 2024-05-23 | MANCHESTER KEITH S Director | Grant or award · Stock Option (Right to Buy) | +67,000 | 67,000 | ||
| 2024-05-23 | HENRIQUES RICHARD C JR Director | Grant or award · Stock Option (Right to Buy) | +67,000 | 67,000 | ||
| 2024-05-23 | Meyers James R Director | Grant or award · Stock Option (Right to Buy) | +67,000 | 67,000 | ||
| 2024-05-23 | Rewolinski Melissa Director | Grant or award · Stock Option (Right to Buy) | +67,000 | 67,000 | ||
| 2024-05-23 | Torti Frank Director | Grant or award · Stock Option (Right to Buy) | +67,000 | 67,000 | ||
| 2024-02-02 | Sims Karen Chief Medical Officer | Sale 10b5-1 | −4,358 | $2.31 | $10K | 125,542 |
| 2024-02-02 | HASTINGS DAVID C Chief Financial Officer | Sale 10b5-1 | −9,593 | $2.31 | $22K | 181,907 |
Page 3 of 8 · 141 trades